Literature DB >> 1645961

Alzheimer's disease amyloid beta-clipping enzyme (APP secretase): identification, purification, and characterization of the enzyme.

K Tagawa1, T Kunishita, K Maruyama, K Yoshikawa, E Kominami, T Tsuchiya, K Suzuki, T Tabira, H Sugita, S Ishiura.   

Abstract

Alzheimer's disease (AD) is the most frequent cause of dementia, although no genetic abnormality has been identified. Recent studies have elucidated the molecular defect in AD, including the abnormal deposition of amyloid beta peptide (beta/A4) in senile plaques of affected individuals. Normal brain contains the enzyme, APP secretase, which cleaves inside the beta/A4 portion of the precursor protein (APP); abnormal processing of APP occurs in AD brain. Until now, no evidence has been provided that APP secretase is an intracellular proteinase. We have now prepared two synthetic substrates of APP secretase, both of which contain the cleavage point and are much more sensitive than substrates previously available to identify APP secretase. Using these substrates, we found an intracellular proteinase that has APP secretase activity. This proteinase has been identified as cathepsin B.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645961     DOI: 10.1016/0006-291x(91)91994-n

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.

Authors:  A M Cataldo; J L Barnett; C Pieroni; R A Nixon
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

Review 2.  The role of the amyloid protein precursor (APP) in Alzheimer's disease: does the normal function of APP explain the topography of neurodegeneration?

Authors:  D H Small
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

3.  Characterization of Cerebrospinal Fluid BACE1 Species.

Authors:  Inmaculada Lopez-Font; Claudia P Boix; Henrik Zetterberg; Kaj Blennow; Javier Sáez-Valero
Journal:  Mol Neurobiol       Date:  2019-07-09       Impact factor: 5.590

Review 4.  The role of beta-amyloid in the development of Alzheimer's disease.

Authors:  K Ii
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

5.  Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer's disease, parkinsonism-dementia complex on Guam, and senile dementia and in the aged.

Authors:  K Ii; H Ito; E Kominami; A Hirano
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 6.  The role of beta-amyloid peptide in Alzheimer's disease.

Authors:  A LeBlanc
Journal:  Metab Brain Dis       Date:  1994-03       Impact factor: 3.584

7.  Genetic and physical mapping of the progressive epilepsy with mental retardation (EPMR) locus on chromosome 8p.

Authors:  S Ranta; A E Lehesjoki; A Hirvasniemi; J Weissenbach; B Ross; S M Leal; A de la Chapelle; T C Gilliam
Journal:  Genome Res       Date:  1996-05       Impact factor: 9.043

Review 8.  Molecular and cellular biology of Alzheimer amyloid.

Authors:  C A Marotta; R E Majocha; B Tate
Journal:  J Mol Neurosci       Date:  1992       Impact factor: 3.444

9.  Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme.

Authors:  J R McDermott; A M Gibson
Journal:  Neurochem Res       Date:  1997-01       Impact factor: 3.996

10.  Characterization of endogenous APP processing in a cell-free system.

Authors:  A M Brown; A Potempska; D Tummolo; M A Spruyt; J S Jacobsen; J Sonnenberg-Reines
Journal:  Age (Omaha)       Date:  1998-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.